Back to Search
Start Over
Real‐life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME program
- Source :
- International Journal of Cancer, International Journal of Cancer, 2019, 145 (12), pp.3359-3369. ⟨10.1002/ijc.32402⟩, International Journal of Cancer, Wiley, 2019, 145 (12), pp.3359-3369. ⟨10.1002/ijc.32402⟩
- Publication Year :
- 2019
- Publisher :
- Wiley, 2019.
-
Abstract
- International audience; Eribulin mesylate (EM) was recently approved for metastatic breast cancer (MBC) chemotherapy (CT) in late lines by the FDA, with debated results in second line. We evaluated outcomes in breast cancer patients receiving EM as second, third and fourth line in a national real-life cohort of 16,703 consecutive MBC patients initiating their first metastatic therapeutic line between 2008 and 2014. Primary and secondary objectives were overall survival (OS) and progression-free survival (PFS). An imbalance was seen for HER2+ tumors and concomitant anti-HER2 targeted therapies use, we thus performed a subanalysis in HER2- patients. PFS and OS were significantly better in EM patients in third and fourth lines, compared to "Other chemotherapies" patients (PFS: 4.14 vs. 3.02 months, p = 0.0010; 3.61 vs. 2.53 months, p = 0.0102, third and fourth-line; OS: 11.27 vs. 7.65 months, p = 0.0001; 10.91 vs. 5.95 months, p
- Subjects :
- Oncology
Cancer Research
medicine.medical_specialty
Receptor, ErbB-2
[SDV]Life Sciences [q-bio]
medicine.medical_treatment
Population
Antineoplastic Agents
Breast Neoplasms
Disease-Free Survival
law.invention
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Breast cancer
real-life cohort
Randomized controlled trial
law
Internal medicine
Humans
Medicine
Furans
education
eribulin
Aged
Retrospective Studies
Chemotherapy
education.field_of_study
business.industry
Ketones
Middle Aged
medicine.disease
Metastatic breast cancer
Progression-Free Survival
3. Good health
chemistry
030220 oncology & carcinogenesis
Concomitant
Cohort
Female
metastatic breast cancer
business
Eribulin
Subjects
Details
- ISSN :
- 10970215 and 00207136
- Volume :
- 145
- Database :
- OpenAIRE
- Journal :
- International Journal of Cancer
- Accession number :
- edsair.doi.dedup.....6441a3dfbca22b766c5adb6c281873ca